Assessing the efficacy of targeted therapy using circulating epithelial tumor cells (CETC): The example of SERM therapy monitoring as a unique tool to individualize therapy

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 5, 2011, Pages 821-828

  Pachmann, Katharina ^a   Camara, Oumar ^a   Kohlhase, Annika ^a   Rabenstein, Carola ^b   Kroll, Torsten ^a   Runnebaum, Ingo B ^a   Hoeffken, Klaus ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF BAYREUTH   (Germany)

Author keywords

Breast cancer; Circulating epithelial tumor cells; Hormone therapy

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN; TRASTUZUMAB;

ADULT; ARTICLE; BLOOD VOLUME; BREAST CANCER; CANCER RELAPSE; CELL CYCLE G1 PHASE; CIRCULATING EPITHELIAL TUMOR CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; FEMALE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR CELL; TUMOR VOLUME;

BREAST NEOPLASMS; EPITHELIAL CELLS; FEMALE; HUMANS; INDIVIDUALIZED MEDICINE; MIDDLE AGED; NEOPLASTIC CELLS, CIRCULATING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 79955681835     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0942-4     Document Type: Article

References (33)

1. Bidard FC, Mathiot C, Delaloge S et al (2010) Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. Ann Oncol 21:729-733
2. Bonadonna G, Moliterni A, Zambett M et al (2005) 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: Cohort study. BMJ 330:217-720
3. Bonneterre J (1992) Meta-analysis of adjuvant medical treatment in breast cancers. Ten year results. Bull Cancer 79:459-464
4. Camara O, Kavallaris A, Nöschel H, Rengsberger M, Jörke C, Pachmann K (2006) Seeding of epithelial cells into circulation during surgery for breast cancer: the fate of malignant and benign mobilized cells. World J Surg Oncol 4:67
5. Camara O, Rengsberger M, Egbe A et al (2007) The relevance of circulating epithelial tumour cells (CETC) for therapy monitoring during neoadjuvant (primary systemic) chemotherapy in breast cancer. Ann Oncol 18:1484-1492 (Pubitemid 47365480)
6. Cianfrocca M, Gradishar WJ (2005) Controversies in the therapy of early stage breast cancer. Oncologist 10:766-779 (Pubitemid 43152694)
7. Comans FA, Doggen CJ, Attard G et al (2010) All circulating EpCAM + CK + CD45 objects predict overall survival in castration resistant prostate cancer. Ann Oncol. doi:10.1093/annonc/mdg030
8. Doughty JC (2008) A review of the BIG results: the Breast International Group 1-98 trial analyses. The Breast 17(S1):S9-S14
9. EBCTCG (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 354:1451-1467
10. Epstein RJ (2005) Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment. Clin Cancer Res 11:5337-5341
11. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor - positive breast cancer. J Clin Oncol 22:3309-3315 (Pubitemid 41103687)
12. Fleisher TA, Marti GE (2001) Detection of unseparated human lymphocytes by flow cytometry. Curr Protoc Immunol Chap 7:Unit 7.9. doi:10.1002/0471142735. im0707s08
13. Gaston C, Kolesar J (2008) Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer. Clin Adv Hematol Oncol 6:825-833
14. Heel RC, Brogden RN, Speight TM, Avery GS (1978) Tamoxifen: a review of its pharmacological properties and therapeutic use in the treatment of breast cancer. Drugs 16:1-24 (Pubitemid 8365347)
15. Hind D, Ward S, De Nigris S, Simpson E, Carroll C, Wyld L (2007) Hormonal therapies for early breast cancer: systematic review and economic evaluation. Health Technol Assess 11:1-134, iii-iv, ix-xi
16. Ingle JN, Tu D, Pater JL et al (2006) Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99:295-300 (Pubitemid 44337921)
17. Jordan VC (2008) The 38th David A. Karnofsky lecture: the paradoxical actions of estrogen in breast cancer - survival or death? J Clin Oncol 26:3073-3082
18. Kaufmann M, Jonat W, Hilfrich J et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after 2 years of treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 25:4639-4641
19. Lobodasch K, Dengler R, Fröhlich F et al (2007) Quantification of circulating tumour cells for monitoring of adjuvant therapy in breast cancer: an increase in cell number at completion of therapy is a predictor of early relapse. Breast 16:211-218 (Pubitemid 46508655)
20. Mamounas EP, Jeong JH, Wickerham DJ et al (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the national surgical adjuvant breast and bowel project B-33 trial. J Clin Oncol 26:1965-1971
21. Meng S, Tripathy D, Frenkel EP et al (2004) Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 10:8152-8162 (Pubitemid 40053373)
22. Miller MC, Doyle GV, Terstappen LWMM (2010) Significance of circulating tumor cells detected by the cellsearch system in patients with metastatic breast colorectal and prostate cancer. J Oncol 2010:617421
23. Molloy T, van't Veer LJ (2008) Recent advances in metastasis research. Curr Opin Genet Dev 18:35-41
24. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339:1609-1618
25. Owusu C, Buist DS, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:523-526
26. Pachmann K (2005) Longtime recirculating tumor cells in breast cancer patients. Clin Cancer Res 11:5657-5658
27. Pachmann K, Clement JH, Schneider CP et al (2005) Standardized quantification of circulating peripheral tumor cells from lung and breast cancer. Clin Chem Lab Med 43:617-627 (Pubitemid 41460612)
28. Pachmann K, Camara O, Kavallaris A et al (2008) Monitoring the response of circulating epithelial tumor cells (CETC) to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 26:1208-1215
29. Rabaglio M, Aebi S, Castiglione-Gertsch M (2007) Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference. Lancet Oncol 8:940-949 (Pubitemid 47488069)
30. Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14:2738-2746 (Pubitemid 26329660)
31. Senn HJ (1968) Adjuvant chemotherapy of breast cancer: an international review and the Swiss experience. Arch Geschwulstforsch 56:425-433
32. Souhami L, Kyounghwa B, Pilepich M, Sandler H (2009) Impact of the duration of adjuvant hormonal therapy in patients with locally advanced prostate cancer treated with radiotherapy: a secondary analysis of RTOG 85-31. J Clin Oncol 27:2137-2143
33. van der Hage JA, Mieog JS, van de Vijver MJ, van der Velde CJ, European Organization for Research and Treatment of Cancer (2007) EYcacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis. Breast Cancer Res 9:R70